Free Trial
→ A new type of AI could unleash gains of up to 10,000% (From Brownstone Research) (Ad)tc pixel
NASDAQ:PTIX

Atrinsic Q2 2025 Earnings Report

Atrinsic logo
$0.77 -0.01 (-0.78%)
As of 10/2/2026 12:23 PM Eastern
ProfileEarnings HistoryForecast

Atrinsic EPS Results

Actual EPS
-$1.37
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Atrinsic Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Atrinsic Announcement Details

Quarter
Q2 2025
Date
9/10/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Atrinsic's next earnings date is estimated for Tuesday, November 17, 2026, based on past reporting schedules.

Conference Call Resources

Atrinsic Earnings Headlines

Atrinsic (NASDAQ:PTIX) Stock Price Down 5.1% - Time to Sell?
September 24, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31042980
Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates
July 30, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/30/3124067/0/en/protagenic-therapeutics-announces-grant-of-new-patent-in-japan-for-its-modified-stilbenoid-program-drug-candidates.html
WATCH THIS BEFORE DECEMBER 8th!!
James Altucher says a quiet government filing could reveal Elon Musk's biggest move yet, and almost nobody has noticed it. Altucher believes the filing could matter to as many as 1,806,000 Americans in the years ahead. He explains why Musk buried it and what it could mean, free of charge.tc pixel
October 4 at 1:00 AM  |  Paradigm Press (Ad)
Protagenic Therapeutics, Inc. (PTIX) - Yahoo Finance
June 24, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/quote/PTIX/news/
Protagenic & Phytanix Merge in All-Stock Move, Sparking Retail Frenzy
May 29, 2025  |  msn.comhttps://www.msn.com/en-us/money/general/protagenic-phytanix-merge-in-all-stock-move-sparking-retail-frenzy/ar-AA1FJicU
Protagenic Therapeutics swaps warrants for shares
May 21, 2025  |  uk.investing.comhttps://uk.investing.com/news/sec-filings/protagenic-therapeutics-swaps-warrants-for-shares-93CH-4095880
See More Atrinsic Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Atrinsic? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atrinsic and other key companies, straight to your email.

About Atrinsic

Atrinsic (NASDAQ:PTIX), Inc. was an internet marketing and digital media company that developed and operated online consumer brands and provided performance-based marketing services. Its activities included customer acquisition, advertising, lead generation and the distribution of digital content and services through online channels.

The company underwent a strategic transformation and later changed its name to Protagenic Therapeutics, Inc. As part of that transition, its business focus shifted away from internet marketing toward biotechnology and the development of peptide-based therapeutics. The company’s later work has centered on treatments for stress-related and anxiety disorders.

Atrinsic’s historical operations primarily served consumers and advertisers through internet-based platforms. Publicly available information about its former leadership, geographic reach and detailed operating history is limited, so a more comprehensive description of those aspects cannot be provided reliably.

View Atrinsic Profile
Earnings Tools